UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2942-2962

2013

Volltextzugriff (PDF)

Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update

Journal of clinical oncology, 2013-03, Vol.31 (7), p.961-965

2013

Volltextzugriff (PDF)

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

Journal of clinical oncology, 2008-02, Vol.26 (5), p.778-785

2008

Volltextzugriff (PDF)

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

Cancer prevention research (Philadelphia, Pa.), 2010-06, Vol.3 (6), p.696-706

2010

Volltextzugriff (PDF)

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

Journal of clinical oncology, 2011-06, Vol.29 (17), p.2327-2333

2011

Volltextzugriff (PDF)

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

The New England journal of medicine, 2010-06, Vol.362 (22), p.2053-2065

2010

Volltextzugriff (PDF)

American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting

Journal of clinical oncology, 2006-11, Vol.24 (31), p.5091-5097

2006

Volltextzugriff (PDF)

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

Journal of clinical oncology, 2005-11, Vol.23 (31), p.7811-7819

2005

Volltextzugriff (PDF)

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

Journal of clinical oncology, 2009-07, Vol.27 (19), p.3235-3258

2009

Volltextzugriff (PDF)

Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer

Journal of clinical oncology, 2011-11, Vol.29 (31), p.4160-4167

2011

Volltextzugriff (PDF)

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial

Journal of clinical oncology, 2008-04, Vol.26 (12), p.1965-1971

2008

Volltextzugriff (PDF)

Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention

Current drug targets, 2011-12, Vol.12 (13), p.1874-1887

Vogel, Victor G

2011

Volltextzugriff (PDF)

Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial

Journal of clinical oncology, 2011-03, Vol.29 (9), p.1110-1116

2011

Volltextzugriff (PDF)

Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2

Oncogene, 2004-07, Vol.23 (33), p.5594-5606

2004

Volltextzugriff (PDF)

Implementation of Risk-reducing Strategies for Breast Cancer is Long Overdue

Cancer prevention research (Philadelphia, Pa.), 2021-01, Vol.14 (1), p.1-4

Vogel, Victor G

2021

Volltextzugriff (PDF)

Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Journal of clinical oncology, 2008-06, Vol.26 (16), p.2644-2652

2008

Volltextzugriff (PDF)

Identifying and Screening Patients at Risk of Second Cancers

Cancer epidemiology, biomarkers & prevention, 2006-11, Vol.15 (11), p.2027-2032

Vogel, Victor G

2006

Volltextzugriff (PDF)

Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention

Cancer discovery, 2013-07, Vol.3 (7), p.812-825

2013

Volltextzugriff (PDF)

Breast cancer risk reduction: Notable achievements and remaining challenges

The breast journal, 2020-01, Vol.26 (1), p.86-91

Vogel, Victor G.

2020

Volltextzugriff (PDF)

American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition

Journal of clinical oncology, 2002-08, Vol.20 (15), p.3328-3343

2002

Volltextzugriff (PDF)

Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer

Proceedings of the National Academy of Sciences - PNAS, 2010-12, Vol.107 (50), p.21725-21730

2010

Volltextzugriff (PDF)

American Society of Clinical Oncology Policy Statement: The Role of the Oncologist in Cancer Prevention and Risk Assessment

Journal of clinical oncology, 2009-02, Vol.27 (6), p.986-993

2009

Volltextzugriff (PDF)

Nonsteroidal Anti-inflammatory Drug Use and Serum Total Estradiol in Postmenopausal Women

Cancer epidemiology, biomarkers & prevention, 2008-03, Vol.17 (3), p.680-687

2008

Volltextzugriff (PDF)

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial

Expert review of anticancer therapy, 2009-01, Vol.9 (1), p.51-60

Vogel, Victor G

2009

Volltextzugriff (PDF)

1 – 25 von 216

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(201)
Mit Volltextzugriff
(177)

Publikationsform

Sprache

Englisch
(215)
Japanisch
(22)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(141)
Science & Technology
(134)
Life Sciences & Biomedicine
(131)
Female
(117)
Oncology
(86)
Middle Aged
(67)
Breast Neoplasms - Prevention & Control
(54)
Biological And Medical Sciences
(51)
Medical Sciences
(51)
Adult
(50)
Aged
(48)
Breast Cancer
(46)
Risk Factors
(43)
Tumors
(37)
Tamoxifen - Therapeutic Use
(35)
Breast Neoplasms - Epidemiology
(26)
Gynecology. Andrology. Obstetrics
(26)
Mammary Gland Diseases
(26)
Risk Assessment
(25)
Breast Neoplasms - Drug Therapy
(20)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline

Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update

Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction

Estrogen Receptor (ESR1) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor–Positive Breast Cancer

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial

Early cancer diagnoses through BRCA1/2 screening of unselected adult biobank participants

Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention

Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial

Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2

Implementation of Risk-reducing Strategies for Breast Cancer is Long Overdue

Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Identifying and Screening Patients at Risk of Second Cancers

Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention

Breast cancer risk reduction: Notable achievements and remaining challenges

American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition

Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer

American Society of Clinical Oncology Policy Statement: The Role of the Oncologist in Cancer Prevention and Risk Assessment

Nonsteroidal Anti-inflammatory Drug Use and Serum Total Estradiol in Postmenopausal Women

The NSABP Study of Tamoxifen and Raloxifene (STAR) trial

Suchergebnisse filtern